Home>>Signaling Pathways>> MAPK Signaling>> RSK>>Pluripotin

Pluripotin (Synonyms: SC1)

Catalog No.GC17407

dual inhibitor of extracellular signal-regulated kinase 1 (ERK1, MAPK3) and RasGAP

Products are for research use only. Not for human use. We do not sell to patients.

Pluripotin Chemical Structure

Cas No.: 839707-37-8

Size Price Stock Qty
10mM (in 1mL DMSO)
$108.00
In stock
2mg
$59.00
In stock
5mg
$89.00
In stock
10mg
$158.00
In stock
25mg
$315.00
In stock
50mg
$558.00
In stock
100mg
$720.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Pluripotin is a dual inhibitor of ERK1 and RasGAP with KDs of 98 nM and 212 nM, respectively. Pluripotin also inhibits RSK1, RSK2, RSK3, and RSK4 with IC50s of 0.5, 2.5, 3.3, and 10.0 µM, respectively.

Pluripotin (SC-1) inhibits Abl1, p70S6K, PLK2, RSK1, RSK2, RSK3, RSK4 with IC50s of 0.005, 1.4, 2.2, 0.5, 2.5, 3.3, 10.0 µM,respectively. Pluripotin (SC-1) decreases cell growth for 7 colon tumor cell lines. After a five day exposure to 0.1 µM SC-1, the seven colon tumor lines are evaluated for changes in cell number and viability. There is a statistically significant decrease in cell number but >95% viability[2].

References:
[1]. Chen S, et al. Self-renewal of embryonic stem cells by a small molecule. Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17266-71.
[2]. Mertins SD, et al. A small molecule (pluripotin) as a tool for studying cancer stem cell biology: proof of concept. PLoS One. 2013;8(2):e57099.

Reviews

Review for Pluripotin

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Pluripotin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.